Description
Tirzepatide: An Innovative Treatment for Obesity and Type 2 Diabetes
Tirzepatide is a revolutionary peptide that received approval from the U.S. Food and Drug Administration (FDA) in May 2022 as a medication for patients with type 2 diabetes. But what exactly is Tirzepatide, and how can it help?
What is Tirzepatide?
Tirzepatide is a dual-action substance that combines the properties of a GLP-1 receptor agonist (glucagon-like peptide-1) and a GIP agonist (glucose-dependent insulinotropic polypeptide). These two hormones play a key role in regulating blood sugar levels. Tirzepatide works by increasing insulin secretion, improving insulin sensitivity, lowering post-meal blood sugar, reducing glucagon secretion, improving lipid metabolism, and delaying gastric emptying.
As a result, people using Tirzepatide may experience significant weight loss—clinical studies have shown that some patients lost up to 20% of their body weight while taking this medication.
Clinical Studies and Benefits
In the SURPASS-3 clinical trial, Tirzepatide demonstrated impressive liver fat–reducing properties, even at low doses. In some patients, liver fat content dropped from 27% to 3% within a year.
Advantages of Tirzepatide:
Effective in fighting obesity and overweight
Considered a successor to the hard-to-access Ozempic in Poland
High safety profile
Reduces appetite
Delays gastric emptying
Increases insulin sensitivity and secretion
Suppresses glucagon secretion
Regulates blood glucose without risk of hypoglycemia
Requires only one injection per week
Dosage
Tirzepatide is administered subcutaneously. Treatment begins with a dose of 1 mg per week, which can be gradually increased, up to a maximum of 15 mg per week. The medication can be taken regardless of the time of day or meals.
Side Effects
Some gastrointestinal issues may occur while using Tirzepatide, including nausea, vomiting, loss of appetite, upper abdominal discomfort, stomach pain, or constipation.
Reviews
There are no reviews yet.